Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
A 37-year-old shared 3 months of hair loss progress using HIMS oral finasteride, minoxidil, biotin, dermarolling, and ketoconazole shampoo. They noticed reduced shedding, no significant side effects, and advised against using Nutrafol.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
Eating 1g of broccoli seeds five days a week may help with hair regrowth due to their high sulforaphane content. However, caution is advised due to potential health risks from erucic acid in the seeds.
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
The conversation discusses choosing between titanium fixed needles and a pen with disposable needles for hair loss treatment at a 1.5mm depth. The preference is for disposable needles for better sanitization.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
The user is experiencing asymmetrical hair loss at the frontal hairline and is concerned about potential conditions like frontal fibrosing alopecia. They have started using finasteride and pumpkin seed oil to address the issue.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user experienced hair regrowth and stronger dreadlocks after six months on finasteride, despite initial shedding and reduced libido. They plan to continue the treatment, possibly adjusting the dosage or adding topical treatments.
The user reports improvement in temple hair after three weeks of using finasteride, minoxidil, ketoconazole, microneedling, stemoxydine, and follicopeptide. They note visible progress by maintaining the same hair length for comparison.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.
A user's 18-month hairline progress using minoxidil, finasteride, Nizoral, microneedling, and scalp massage. They share their routine and discuss treatment effectiveness and photo order confusion.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.
The user is discussing hair regrowth after 3.5 months of using finasteride, questioning if the new growth is baby hairs. They compare photos from December to the present to assess progress.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
The post and conversation are about hair transplant tips and experiences. The user emphasizes thorough planning, essential packing, and post-surgery care, and regrets not using finasteride earlier.
ShaneMorcs shared updated hair comparison photos and believes he's made progress. People commented on his improvement, asked about potential side effects, and inquired about the treatments he's using.
User "al_ick" shares progress with topical fin, min, tret, and micro needling for hair loss, showing good results. They use hims fin and min combination spray, applying 5-7 sprays for better coverage.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.